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A B S T R A C T
Venous thromboembolism (VTE), manifesting as either deep vein thrombosis or pulmonary embolism, is
common worldwide including in Japan. The number of patients clinically diagnosed with VTE is
increasing with the majority of cases occurring out-of-hospital and of milder severity. Cancer is the
largest risk factor for VTE and VTE in cancer patients confers an increased 1-year mortality rate. However,
the majority of VTE cases are considered ‘‘idiopathic’’ or ‘‘unprovoked.’’ The limited efﬁcacies of
unfractionated heparin and warfarin have stimulated the development of new anticoagulant therapies.
Recently, parenteral and oral administration of the Xa inhibitors fondaparinux and edoxaban,
respectively, was approved in Japan. These agents have the potential to provide safer and more
efﬁcacious treatment options for VTE. Although further randomized studies are required to validate the
utility of these agents, they are expected to substantially improve quality of life in VTE patients. This
review summarizes the current status of VTE management in Japan focusing on current epidemiology
and recent advances in anticoagulant therapy.
 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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Venous thromboembolism (VTE), manifesting as either deep vein
thrombosis (DVT) or pulmonary embolism (PE), is common and
results in long-term morbidity and mortality affecting >1–2 per* Corresponding author at: Department of Cardiology and Nephrology, Mie
University Graduate School of Medicine, 2-174, Edobashi, Tsu 514-8507, Japan.
Tel.: +81 59 231 5015; fax: +81 59 231 5201.
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http://dx.doi.org/10.1016/j.jjcc.2015.03.012
0914-5087/ 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rights1000 individuals each year in the USA and Europe [1–3]. Patients
with VTE have a high and persistent risk of recurrence, including
nonfatal and fatal PE. The cumulative incidence of recurrent VTE is
estimated to be at least 10% at 1 year and 30% at 5 years following
withdrawal of anticoagulant therapy [4]. Several clinical guidelines
for VTE have been published in the USA and Europe including the
‘‘2014 ESC (European Society of Cardiology) Guidelines on the
Diagnosis and Management of Acute Pulmonary Embolism’’ [5],
‘‘Antithrombotic therapy for VTE disease: Antithrombotic Therapy
and Prevention of Thrombosis, 9th ed: American College of Chest
Physicians Evidence-Based Clinical Practice Guidelines (2012)’’ reserved.
Fig. 1. Changes in the number of clinically diagnosed cases of pulmonary embolism
in Japan over time.
Information compiled from Refs. [14–18].
M. Nakamura et al. / Journal of Cardiology 66 (2015) 451–459452[6], and ‘‘Management of massive and submassive pulmonary
embolism, iliofemoral deep vein thrombosis, and chronic thrombo-
embolic pulmonary hypertension: a scientiﬁc statement from the
American Heart Association (2012)’’ [7].
Concurrently, because of increased prevalence of venous
thromboembolic risk factors through continued westernization of
Japanese life and an aging society, the medical and social impacts of
VTE have recently received increased attention. The ﬁrst Japanese
guidelines for the treatment of VTE were published in 2004 and
revised in 2009 [8]. However, several recommendations were not
supported by clinical evidence from Japanese patients, and data
regarding real-world practice and guideline compliance are lacking.
Anticoagulant therapy is the cornerstone of VTE treatment.
Standard anticoagulation treatment in Japan involves the use of
unfractionated heparin (UFH), overlapped and followed by
warfarin. Because of the need for frequent monitoring to assess
bleeding risk, the efﬁcacy of UFH and warfarin is often questioned,
despite limited data on VTE treatment in Japanese patients. NewFig. 2. Relative risk of perioperative symptomatic pulmonary embolism based on the 20
2002, yp < 0.01 vs. 2006.
From Kuroiwa et al. [19] with permission.parenteral and oral anticoagulant therapies overcome some
limitations of standard therapy, including the need for injection
and regular dose adjustments resulting from laboratory monitor-
ing [9–13]. Recently, fondaparinux and edoxaban have been
approved as alternative therapeutic options to UFH and warfarin in
Japan and are expected to improve the prognosis of VTE.
The objective of this review is to discuss current VTE
epidemiology and advances in anticoagulant therapy in Japan to
provide a perspective on the clinical management of VTE.
Incidence of venous thromboembolism in Japan
Fig. 1 shows the number of clinically diagnosed PE cases in Japan
measured by questionnaire surveys [14–18]. The number of patients
with PE has increased 4.6-fold in the past 15 years with the annual
incidence estimated to be 126 per 1,000,000 people in Japan in
2011. In contrast, as shown in Fig. 2, survey results from the Japanese
Society of Anesthesiologists demonstrate that the incidence of
postoperative PE signiﬁcantly decreased from 2004 when Japanese
VTE prophylaxis guidelines were published [19]. The proportions of
PE occurring in hospital were 51% and 30% in 2000–2003 and 2011,
respectively (Fig. 3A) [18,20]. Submassive and nonmassive severity
types of PE were the most frequently diagnosed in 2000–2003 and
2011, respectively (Fig. 3B) [18,20]. In addition, an isolated calf vein
thrombosis was recently found to be the most common diagnosed
form of DVT (Fig. 3C) [18]. These results indicate that the number of
VTE diagnoses occurring out-of-hospital and milder severities of VTE
appear to be rapidly increasing in Japan. This change may be because
of improved diagnostic accuracy resulting from rising awareness
among medical staff, increased recognition of VTE, and advances in
imaging modalities.
Risk factors for venous thromboembolism in Japan
Multiple risk factors, including genetic and acquired, or
environmental, risk factors, are involved in the development of
VTE. The Japan VTE Treatment Registry (JAVA) study is a
nationwide, observational, multicenter, Japanese cohort study of
consecutive patients with objectively-conﬁrmed symptomatic PE,02 incidence in Japan. Error bars represent 95% conﬁdential intervals. **p < 0.01 vs.
Fig. 3. Clinical images of venous thromboembolism in Japan. (A) Site of pulmonary embolism development (in-hospital or out-of-hospital). Information for the years 2000–
2003 and 2011 was compiled from Nakamura et al. [20] and Ota et al. [18], respectively. (B) Distribution of pulmonary embolism severity. Information for the years 2000–
2003 and 2011 was compiled from Nakamura et al. [20] and Ota et al. [18], respectively. (C) Graph representing proximal venous thrombus development. Information was
compiled from Ota et al. [18]. There was distribution of deep vein thrombosis severity.
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between April 2009 and March 2010 that retrospectively identiﬁed
1076 patients with VTE [21]. This registry revealed recent trends in
risk factor prevalence in Japan (Table 1). A history of recent surgery
was reported in 17.8% of VTE cases. Postoperative VTE has been
signiﬁcantly decreased as a result of in-hospital thromboprophy-
laxis. Among risk factors for VTE, a medical history of cancer was
found to be the most prevalent at 27.0% in VTE patients. An
increased mortality rate was observed in patients with cancer
(30.3% per patient-year) than in those without cancer (3.7% per
patient-year). These cancer patients were found to be more likely
to have received subtherapeutic durations or levels of antic-
oagulation because of concerns regarding bleeding complications
and the association between warfarin initiation and improved
prognosis in cancer patients. Approximately three-quarters of the
deaths occurred in patients with a history of cancer at the time of
VTE diagnosis. Consequently, improving VTE management in
patients with cancer may lead to an overall decrease in all-cause
mortality in patients diagnosed with VTE.
One of the most notable ﬁndings of the JAVA study was the
observation that 43.2% of all registered VTEs were considered
‘‘idiopathic’’ or ‘‘unprovoked’’ without an associated trigger or an
identiﬁed chronic risk factor.
The major inheritable risk factors in the Japanese population are
the K196E mutation of protein S (protein S Tokushima) and
deﬁciencies in protein C, protein S, and antithrombin [22,23]. Fac-
tor V Leiden and prothrombin G20210A gene mutation associated
with VTE are highly prevalent in Caucasian populations but
virtually nonexistent in the Japanese population [24]. Conversely,
protein S Tokushima is observed exclusively in Japanese popula-
tions [25]. These genetic differences may be one explanation for
ethnic variability in the observed incidence of VTE.
Indeﬁnite anticoagulation may be required in cancer patients
with VTE, patients with unprovoked VTE, and VTE patients with
inheritable risk factors.
Management and outcome of venous thromboembolism in
Japan
Fig. 4 shows an example of a treatment algorithm for PE from
the second Japanese guidelines for the diagnosis, treatment, andTable 1
Risk factors of venous thromboembolism.
Risk factor Overall
n = 1076
(100%)
PE with or
without DVT
n = 338 (31.4%)
DVT alone
n = 738
(68.6%)
Obesity (BMI 30) 59 (5.5) 23 (6.8) 36 (4.9)
Recent surgery
(within 3 months)
192 (17.8) 56 (16.6) 136 (18.4)
Cancer 290 (27.0) 78 (23.1) 212 (28.7)
Heart disease 72 (6.7) 22 (6.5) 50 (6.8)
Respiratory disease 49 (4.6) 19 (5.6) 30 (4.1)
Severe infection 30 (2.8) 8 (2.4) 22 (3.0)
Severe injury 7 (0.7) 3 (0.9) 4 (0.5)
Fracture 49 (4.6) 14 (4.1) 35 (4.7)
Cesarean delivery
(within 14 days)
3 (0.3) 3 (0.9) 0 (0.0)
History of VTE 66 (6.1) 21 (6.2) 45 (6.1)
Thrombophilia 44 (4.1) 12 (3.6) 32 (4.3)
Lower limb paresis 32 (3.0) 10 (3.0) 22 (3.0)
Varicosis 45 (4.2) 11 (3.3) 34 (4.6)
Estrogen and/or HRT 28 (2.6) 8 (2.4) 20 (2.7)
Central venous catheter 43 (4.0) 8 (2.4) 35 (4.7)
Immobilization 225 (20.9) 65 (19.2) 160 (21.7)
From Ref. [21] with permission.
Data given as n (%).
BMI, body mass index; DVT, deep vein thrombosis; PE, pulmonary embolism;
HRT, hormone replacement therapy; VTE, venous thromboembolism.prevention of pulmonary embolism and deep vein thrombosis
issued in 2009 [8]. Anticoagulation is recommended as ﬁrst-line
therapy for treating VTE as in the USA and Europe. In addition,
thrombolysis or vena cava ﬁlter insertion is performed depending on
hemodynamic state and extent of venous thrombus. Fig. 5 shows
changes in treatment approaches for PE in Japan [20,26–28]. PE
management in Japan frequently involves thrombolysis with a high
rate of vena cava ﬁlter insertion, despite low recommendation levels
for these treatment procedures in the USA and Europe.
Until the spring of 2011, the standard anticoagulation
treatment in Japan for the acute phase of VTE involved intravenous
UFH, with routine monitoring of activated partial thromboplastin
time (aPTT) for dose adjustment followed by long-term adminis-
tration of warfarin. One downside of UFH is the necessity for aPTT
monitoring by frequent blood sampling. For this reason, dose
adjustments based on aPTT were subtherapeutic (aPTT 1.5) in
almost 40% of cases in Japanese clinical practice (Table 2). The use
of low-molecular-weight heparin (LMWH) to overcome the
limitations of UFH was already a standard practice in the USA
and Europe 20 years ago, whereas LMWH has yet to be approved
for the treatment of VTE in Japan [29]. Fondaparinux [30], a
synthetic inhibitor of the coagulation factor Xa, was approved as an
alternative to UFH for the treatment of acute VTE in spring of
2011 in Japan, despite being approved in the USA and Europe in
2004. Fondaparinux acts by selectively inhibiting factor Xa activity by
speciﬁcally binding to antithrombin. Unlike UFH, fondaparinux does
not inhibit thrombin activity. The selective inhibition of factor Xa
upstream of thrombin enables efﬁcient inhibition of the coagulation
response without increasing bleeding risk. Fondaparinux is subcuta-
neously administered once daily and does not require dose
adjustments or monitoring of coagulation parameters. Two large
randomized clinical trials of fondaparinux in the USA and Europe,
MATISSE PE [9], an open-labeled trial involving patients with PE, and
MATISSE DVT [31], a double-blind trial involving those with DVT,
demonstrated noninferiority of fondaparinux to UFH and LMWH,
respectively. The safety and efﬁcacy of fondaparinux has also been
examined in a small number of Japanese patients. This study
suggested that once-daily, subcutaneous fondaparinux without
monitoring was as effective and safe as adjusted-dose intravenous
UFH for the initial treatment of VTE in Japanese patients [32].
To prevent recurrent VTE, warfarin therapy after parenteral
anticoagulant therapy was recommended in the 2009 Japanese
guidelines [8]. The duration of warfarin therapy is recommended
to be 3 months in patients with reversible risk factors and at least
3 months in patients with congenital coagulopathy and those with
idiopathic VTE. Furthermore, warfarin should be administered for
an increased duration in patients with cancer and those with
recurrent VTE.
The recommended target prothrombin time–international
normalized ratio (PT–INR) for VTE based on the Japanese guide-
lines is 2.0 (range, 1.5–2.5), lower than the target value (PT–INR,
2.5; range, 2.0–3.0) used in the USA and Europe [33]. In the JAVA
study [21] described above, Japanese clinicians used warfarin for
an average of 6–7 months, despite the 2004 Japanese guidelines
recommending at least 6 months of warfarin usage, with a target
PT–INR in the range of 1.5–2.5 in most cases (Table 2). The
estimated annual incidence of recurrent VTE was 3.6% and the
incidence rate was 4.0 per 100 patient-years in Kaplan–Meier
analyses reported for the JAVA study. However, the incidence rate
was 8.1 per 100 patient-years following completion of warfarin
therapy, while the incidence rate was 2.8 per 100 patient-years
during warfarin therapy (Fig. 6) [34]. The subsequent incidence
rates for all types of bleeding and major bleeding were 8.2% and
3.3% per patient-year, respectively, in this registry. Therefore, the
continued use of warfarin for prolonged periods becomes difﬁcult
to justify when considering the beneﬁt–risk ratio.
Fig. 4. An example treatment algorithm for pulmonary embolism from the second Japanese guidelines for the diagnosis, treatment, and prevention of pulmonary embolism
and deep vein thrombosis. *1 When risk of bleeding is high. *2 Treat complications appropriately with available methods. *3 Unstable hemodynamics consistent with shock or
prolonged hypotension. *4 Condition requiring cardiopulmonary resuscitation or prolonged severe shock. *5 Consider PCPS according to hospital equipment and patient
condition. *6 Select appropriate treatment according to hospital equipment and patient condition. *7 Evaluate based on right ventricular enlargement on echocardiography
and severity of pulmonary hypertension. *8 Presence/absence of DVT, which may have serious effects upon release of emboli causing recurrent embolism. The above
algorithm is an example. Each institution should select appropriate methods according to its healthcare resources. DVT, deep vein thrombosis; PCPS, percutaneous
cardiopulmonary support; IVC, inferior vena cava.
From JCS Joint Working Group [8] with permission.
M. Nakamura et al. / Journal of Cardiology 66 (2015) 451–459 455The limitations of warfarin have stimulated the development
of nonvitamin K antagonist oral anticoagulants (NOACs) for the
treatment of VTE [10–13] among other indications. NOACs
directly inhibit either Factor Xa or thrombin. In contrast to
conventional warfarin, these agents have a rapid onset of action,
shorter half-life, and fewer drug interactions with no necessity
for routine monitoring when administered in ﬁxed doses. For
these reasons, NOACs can be used as replacements of parenteral
anticoagulants and warfarin for initial, long-term, and extended
VTE treatment.0
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Fig. 5. Changes in pulmonary embolism management in Japan over time.
Information from 94.01-06.08 compiled from Refs. [20,21,26–28].In Japan, edoxaban, a once-daily, oral, direct factor Xa inhibitor,
was approved in September 2014 for the treatment of VTE based on
the result of the Hokusai–VTE trial [13]. The Hokusai–VTE trial was a
randomized, multinational, double-blind, noninferiority study that
evaluated the efﬁcacy and safety of heparin followed by edoxaban
60 mg once daily or edoxaban 30 mg once daily in patients with a
creatinine clearance of 30–50 ml per minute, body weight of
60 kg, or in patients who were receiving concomitant treatment
with potent P-glycoprotein inhibitors against heparin overlapped
with and followed by warfarin. Hokusai–VTE demonstrated that.08 03.09  - 06.08
Ancoagulaon
Thrombolysis
Catherter Intervenon
Surgical Therapy
IVC Filter
2011
Table 2
Antithrombotic management (acute and chronic phases).
Overall
n = 1076
PE with or
without DVT
n = 338
DVT alone
n = 738
Thrombolytic 225 (20.9) 87 (25.7) 138 (18.7)
Urokinase 163 (71.8) 41 (47.1) 122 (87.1)
tPA 63 (27.8) 47 (54.0) 16 (11.4)
Parenteral anticoagulant 908 (84.4) 302 (89.3) 606 (82.1)
UFH 864 (80.3) 293 (86.7) 571 (77.4)
aPTT
<1.5 268 (37.6) 91 (35.4) 177 (38.8)
1.5–3 438 (61.4) 166 (64.6) 272 (59.6)
>3 7 (1.0) 0 (0.0) 7 (1.5)
LMWH 45 (4.2) 10 (3.0) 35 (4.7)
Warfarin 956 (88.8) 305 (90.2) 651 (88.2)
Duration (months) 7  4.8 6.4  5.0 7.3  4.7
Target INR
<1.5 65 (6.8) 19 (6.2) 46 (7.1)
1.5–2.5 812 (84.9) 253 (83.0) 559 (85.9)
>2.5 49 (5.1) 22 (7.2) 27 (4.1)
NA 30 (3.1) 11 (3.7) 19 (2.9)
From Ref. [21] with permission.
Data given as n (%) or mean  SD.
DVT, deep vein thrombosis; PE, pulmonary embolism; aPTT, activated partial
thromboplastin time; INR, international normalized ratio; LMWH, low-molecular-
weight heparin; NA, not available (INR performed but unknown or not measured);
tPA, tissue plasminogen activator; UFH, unfractionated heparin.
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standard of care; heparin overlapped with and was followed by
warfarin, and was associated with signiﬁcantly fewer bleeding
events in a broad spectrum of patients with VTE (Fig. 7). The results
of a regional subanalysis of Hokusai–VTE examining East Asia,
including the Japanese population, were consistent with the overall
study [35]. There have been concerns regarding the use of NOACs
causing a higher risk of bleeding among patients with renal
impairment and low body weight. Japanese VTE patients appeared
to be older with impaired creatinine clearance and a lower body
weight (<60 kg) requiring reductions in edoxaban dosages. Despite
edoxaban dose reduction, treatment efﬁcacy was maintained with
signiﬁcantly fewer clinically relevant bleeding events than with
warfarin. Edoxaban 30 mg once daily was already approved for the
prevention of VTE following orthopedic surgery in Japan, and
postmarketing surveillance data found a limited number of bleeding
events with edoxaban without unforeseen safety signals [36].Fig. 6. Cumulative incidence of recurrent venous thromboembolism with or without war
as determined using Kaplan–Meier analysis of patients receiving warfarin therapy. (B) 
analysis following completion of warfarin therapy. JAVA, Japan VTE Treatment Registry
Information for the year 2011 compiled from Ref. [33].Future direction of nonvitamin K antagonist oral
anticoagulants in Japan
NOACs are an effective and safer alternative to warfarin,
particularly in Asian populations, as an increased bleeding
tendency has been reported with its use in Asian populations
compared with Caucasian populations. Therefore, NOACs repre-
sent an important advance in VTE treatment. By streamlining
transition of care, they facilitate out-of-hospital treatment and are
safer and easier to use than warfarin. Furthermore, NOACs can be
used for the treatment of VTE over extended periods.
The treatment of unprovoked VTE, the most common cause of
VTE in Japan, would be improved by indeﬁnite anticoagulation.
Signiﬁcantly lower bleeding rates have been observed in VTE
patients with the use of NOACs. Taken together, NOACs provide
substantial beneﬁts in safety and risk of bleeding compared with
warfarin treatment and offer new therapeutic options for long-
term prevention in cases of unprovoked VTE.
VTE is a common complication in cancer patients, as demon-
strated by the JAVA study. Guidelines in the USA and Europe
recommend treatment with LMWHs for initial and long-term
therapy [5–7]. However, LMWH is not approved as a treatment of
VTE in Japan. Furthermore, the safe use of warfarin in cancer patients
is complex because of frequent changes in nutritional status,
multiple drug interactions, and alterations in liver metabolism
arising from both the disease itself and administered therapies. In
addition, there is a delay of several days between the initiation of
warfarin treatment and the complete anticoagulant effect because
this depends on the clearance of clotting factors from plasma. This
leads to potential therapy interruptions in cancer patients due to
chemotherapy-induced thrombocytopenia prior to surgery or other
invasive procedures. Moreover, cancer patients receiving warfarin
have an increased risk for bleeding in addition to recurrent
thromboembolic events. Therefore, NOACs represent an attractive
therapeutic option in these patients. Theoretically, the capacity of
NOACs to inhibit clot-bound factor Xa or thrombin may offer a
potential advantage over heparins and fondaparinux because NOACs
can neutralize thrombogenic activity of thrombi formed in the
microvascular environment of cancer cells expressing tissue factor
or other procoagulant molecules.
Despite the relatively rapid onset of action of NOACs reaching
peak concentrations within approximately 3 h, clinicians may be
more hesitant of their use in patients with PE than in those withfarin treatment in the JAVA study. (A) An incidence rate of 2.8 per 100 patient-years,
An incidence rate of 8.1 per 100 patient-years, as determined using Kaplan–Meier
.
Fig. 7. Kaplan–Meier cumulative event rates for the primary efﬁcacy outcome and principal safety outcome of the Hokusai–VTE trial. Kaplan–Meier curves (A) are shown for
the ﬁrst occurrence of the primary efﬁcacy outcome of adjudicated symptomatic recurrent venous thromboembolism (VTE), a composite of deep-vein thrombosis or nonfatal
or fatal pulmonary embolism, in the overall study period. The inset shows the same data on an enlarged y-axis. The principal safety outcome (B) was the incidence of
adjudicated clinically relevant bleeding, deﬁned as a composite of major and clinically relevant nonmajor bleeding. The inset shows the same data on an enlarged y-axis.
From Ref. [13] with permission.
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recurrent event compared with those with isolated DVT (Fig. 8)
[21]. Half of these events occurred within 3 months and became
rarer after 6 months. However, the 2014 ESC guidelines on the
diagnosis and management of acute pulmonary embolism state
that patients with low-risk PE should be considered for early
discharge and continuation of treatment at home if proper
outpatient care and anticoagulant treatment can be provided
[5]. More data are required to evaluate the efﬁcacy and safety
of NOACs for the initial treatment of PE. Despite this, transition
and maintenance on NOACs may be more effective than
with warfarin, when patients are initially treated with UFH or
fondaparinux.
Initial treatment of DVT without a heparin lead-in for
outpatient therapy is thought to be a valid indication for the
use of NOACs. However, there is currently a lack of data available to
accurately determine the efﬁcacy and safety of initiating edoxaban
immediately at VTE presentation. A number of trials have indicated
that home treatment is not associated with an increase in
mortality, recurrent VTE, or major bleeding and may be associatedwith improved outcomes [37,38]. From these data, the 2012 ACCP
guidelines state that in patients with DVT of the leg and whose
home circumstances are adequate, initial treatment at home is
recommended over in-hospital treatment [6].
As noted above, the management of isolated distal DVT remains
controversial, despite being a common occurrence [39,40]. Guide-
lines [6] suggest that in patients with acute isolated distal DVT of
the leg and without severe symptoms or risk factors for extension,
serial imaging of the deep veins should be conducted over 2 weeks
from initial anticoagulation. NOACs are safer than warfarin;
therefore, their use in the management of isolated distal DVT
may prove beneﬁcial, despite the majority of isolated distal DVTs
not requiring anticoagulation.
Finally, the suitability of NOACs for the treatment of VTE in
fragile patients, including those with very low body weight,
pregnant women, and those with serious thrombophilia, has not
been established. There are no validated tests allowing assessment
of the antithrombotic effect of NOACs. The management of
bleeding complications resulting from the use of NOACs requires
a rapid and safe reversal agent for factor Xa or thrombin inhibition.
Fig. 8. Cumulative incidence of recurrent venous thromboembolism according to entry diagnosis in the JAVA study. Symptomatic PE with or without DVT (red line) or DVT
alone (blue line). The risk of recurrence was signiﬁcantly higher in patients with an initial diagnosis of PE (with or without DVT) than in those with isolated DVT (Cox
proportional hazard analysis). DVT, deep vein thrombosis; PE, pulmonary embolism; JAVA, Japan VTE Treatment Registry.
From Ref. [21] with permission.
M. Nakamura et al. / Journal of Cardiology 66 (2015) 451–459458Therefore, further studies are required to increase the utility of
NOACs in the treatment of VTE.
Conclusions
This review summarizes the current status of VTE management
in Japan with a focus on current epidemiology and advances in
anticoagulant therapy. The number of clinically diagnosed cases of
VTE continues to increase, with the majority cases of mild severity
where decisions regarding treatment options are most controver-
sial. The largest risk factor for VTE is cancer; however, unprovoked
VTE is much more prevalent. Prolonged warfarin therapy is
challenging in patients with cancer and unprovoked VTE. Recently,
novel anticoagulant agents fondaparinux and edoxaban have been
approved in Japan. These agents have the potential to provide more
convenient and beneﬁcial treatment options for VTE because they
are both safer and more effective than current therapies. Although
further randomized studies are required to fully validate the utility
of these agents, they are expected to improve the quality of life of
patients with VTE.
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